| YU Jing-ping,SUN Zhi-qiang,NI Xin-chu,et al.Clinical effect observation of VEGF expression interfered by Thalidomide combined with radiotherapy in esophageal cancer treatment[J].Chinese Journal of Radiological Medicine and Protection,2012,32(4):369-373 |
| Clinical effect observation of VEGF expression interfered by Thalidomide combined with radiotherapy in esophageal cancer treatment |
| Received:January 12, 2012 |
| DOI：10.3760/cma.j.issn.0254-5098.2012.04.009 |
| KeyWords:Esophageal cancer Radiotherapy Vascular endothelial growth factor Thalidomide |
| FundProject:常州市卫生局重大科技项目(ZD201105) |
| Author Name | Affiliation | E-mail | | YU Jing-ping | Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | SUN Zhi-qiang | Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | NI Xin-chu | Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | WANG Jian | Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | LI Yi | Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | HU Li-jun | Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | LI Dong-qing | Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | SUN Su-ping | Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | ssp56@126.com |
|
| Hits: 5931 |
| Download times: 2753 |
| Abstract:: |
| Objective To prospectively study the dynamic variation of vascular endothelial growth factor (VEGF), the short-term efficiency and the tolerability of the esophageal cancer patients treated by radiotherapy combined with thalidomide.Methods The serum samples of 86 esophageal cancer patients were collected before, during and after the radiotherapy. The VEGF levels were assayed by enzyme-linked immunosorbent assay (ELISA). 3 patients interrupted the treatment because of intolerance radiotherapy.Based on the changes of VEGF level, 32 esophageal cancer cases whose VEGF levels increased or remained were assigned to the group to which thalidomide was given during the whole course of radiotherapy. The rest 51 patients whose VEGF level decreased received radiotherapy without thalidomide during the whole course. In addition, 30 healthy cases were included in control group. Then the efficiency and safety of the introduction of thalidomide in radiotherapy were investigated. Results The VEGF levels of 86 esophageal cancer cases were significantly higher than the 30 healthy control cases (t=5.07, P<0.01), which were also correlated with the primary tumor size(t=4.55,P<0.01), lymph node metastasis(t=7.50,P<0.01), histological type(F=3.40,P<0.01) and clinical stage(t=2.52,P<0.01). However, it was irrelevant to the lesion site, distant metastasis, X-ray pathologic type, gender or age (P﹥0.05). For the thalidomide involved group, the VEGF level after radiotherapy was significantly lower than during radiotherapy (t=2.37, P<0.05) with an effective rate of 71.88%. For the rest 51 cases without using thalidomide, the effective rate was 78.43% yet there was no significant difference between the VEGF levels during and after radiotherapy (t=0.18, P﹥0.05). 62.50% patients reported symptoms of dizzy and burnout after using thalidomide, while this incidence was 15.69% for the rest patients (χ2=19.28,P=0.000). For the groups with or without thalidomide combination, the sleepiness incidences were 18.75% and 1.96%, respectively (χ2=5.168,P=0.023); the Ⅲ-Ⅳ grade esophagitis incidences were 12.50% and 11.76%, respectively (χ2=0.061,P =0.806); the Ⅲ-Ⅳ grade leukocyte decrease incidences were 6.25% and 9.80%, respectively (χ2=0.026,P=0.872); the Ⅲ-Ⅳ grade platelet descend incidences were 3.13% and 5.88%, respectively (χ2=0.002, P=0.965); the Ⅲ-Ⅳ grade nausea and vomiting incidences were 9.38% and 27.45%, respectively (χ2=2.913, P=0.088). No anaphylaxis was observed. Conclusions Thalidomide can decrease the VEGF expression level of esophageal cancer patients. Patients treated with thalidomide show good tolerance and compliance. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
